Research
Early dupilumab use linked to fewer asthma diagnoses in children with EoE
In retrospective data, children with EoE who received dupilumab before age 6 had fewer later asthma diagnoses, but the findings do not establish cause and effect.
An observational study presented at the American College of Allergy, Asthma & Immunology meeting linked dupilumab use before age 6 in children with eosinophilic esophagitis (EoE) to fewer later asthma diagnoses.
MedPage Today reported asthma in 8.1% of children who received dupilumab, compared with 16.0% of children with EoE who never received it, during the subsequent 3.5 years. Healio reported a comparison with oral budesonide: 10.5% of children receiving dupilumab and 16.2% receiving budesonide developed asthma. The reports gave different sample counts and comparison details. MedPage described 698 matched children in each group in its methods, while Healio reported 344 in the dupilumab group and 401 in the budesonide group.
The study was retrospective, and presenter Kayla Steinberger cautioned that it cannot establish cause and effect. Healio reported that stronger prospective studies are needed.


